THE DEAL, AT A GLANCE

Circle Pharma

2/4 reviewed

Circle Pharma

Circle Pharma develops macrocycle cancer medicines designed to reach targets conventional medications cannot.

Circle Pharma raised $92.5M Series E, announced 2026-09-16

01What it doesCircle Pharma develops macrocycle cancer medicines designed to reach targets conventional medications cannot.Source-grounded · automated review · Explore ↗

Checked 2026-10-06 · Review due 2026-10-13

Read supporting source ↗

Our proprietary MXMO™ platform was…

02What happenedCircle Pharma raised $92.5M Series E, announced 2026-09-16From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗

03Why it mattersIts macrocycles may make cancer treatment more comfortable with fewer side effects.Source-grounded · automated review · Explore ↗

Checked 2026-10-06 · Review due 2026-10-13

Read supporting source ↗

The highly selective nature of…

Click a part to explore its evidence. The image is supplied by the cited source.Original record source ↗

Circle Pharma · Financing Record

Explore source-linked visual explanations for Circle Pharma. Unsupported claims are withheld while source review continues.

Record 12423 · Recorded date: 2026-09-16